Stocks Health care INAB
NASDAQ · Health careIN8BIO, Inc. (INAB)
It posted a net loss of $18.7M. At June 30, 2026 it held $18.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
Key facts about IN8BIO, Inc.
- Net worth
- IN8BIO, Inc. has a market value (market cap) of $8.9M at the latest share price, and shareholders' equity of $18.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $12.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 6, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- IN8BIO, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
What IN8BIO, Inc. does
IN8BIO, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker INAB.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$19.4M | -$4.44 | n/a |
| 2024 | n/a | -$30.4M | -$17.05 | n/a |
| 2023 | n/a | -$30M | -$29.91 | n/a |
| 2022 | n/a | -$28.5M | -$40.68 | n/a |
| 2021 | n/a | -$14.7M | -$43.97 | n/a |
| 2021 | n/a | -$8.6M | -$90.34 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What IN8BIO, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026
- August 6, 2026
- August 6, 2026
- June 1, 2026
- May 29, 2026Activist stake changed SCHEDULE 13D/A
- May 18, 2026
- May 7, 2026Form S-8 POS filing S-8 POS
- May 7, 2026Form S-8 POS filing S-8 POS
- May 7, 2026Form S-8 POS filing S-8 POS
Insider trades
What the people running IN8BIO, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| May 27, 2026 | Fairbairn EmilyDirector | Gave as a giftindirect | 724,637 | - |
| December 22, 2025 | Brandt Peter C.Director | Received as pay | 72,464 | $100K |
| December 22, 2025 | Roemer Alan S.Director | Received as pay | 36,232 | $50K |
| December 22, 2025 | Fairbairn EmilyDirector | Received as payindirect | 724,637 | $1M |
| December 22, 2025 | Ho William Tai-WeiPRESIDENT AND CEO, Director, 10% owner | Received as pay | 36,232 | $50K |
| December 22, 2025 | McCall PatrickCHIEF FINANCIAL OFFICER | Received as pay | 7,247 | $10K |
| December 22, 2025 | Rochlin KateChief Operating Officer | Received as pay | 7,247 | $10K |
Who owns INAB
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Lytton Laurence W13G, passive with 1 related filers | 9.99% | August 13, 2026 |
| Alyeska Investment Group, L.P.13G, passive with 2 related filers | 9.9% | February 17, 2026 |
| Stonepine Capital Management, LLC13G, passive with 3 related filers | 9.9% | December 22, 2025 |
| 683 Capital Management, LLC13G, passive with 2 related filers | 7.86% | December 30, 2025 |
Largest institutional holders
Insiders
5 insiders reported holding 284,430 shares in total, about $248K at the last price.
| Holder | Shares |
|---|---|
| Ho William Tai-WeiPRESIDENT AND CEO, Director, 10% owner | 121,168 |
| Brandt Peter C.Director | 95,181 |
| Roemer Alan S.Director | 49,514 |
| McCall PatrickCHIEF FINANCIAL OFFICER | 9,482 |
| Rochlin KateChief Operating Officer | 9,085 |
Questions about INAB
What does IN8BIO, Inc. do?
IN8BIO, Inc. is a company in the Health care sector, listed on NASDAQ as INAB. Its shares trade on NASDAQ under the ticker INAB.
What is IN8BIO, Inc.'s net worth?
IN8BIO, Inc. has a market value (market cap) of $8.9M at the latest share price, and shareholders' equity of $18.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is IN8BIO, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $18.7M.
When did IN8BIO, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from August 13, 2026.
When is IN8BIO, Inc.'s next earnings report?
IN8BIO, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
Similar companies
Compare INAB with
Follow INAB
Get an email when IN8BIO, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values IN8BIO, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.